跳至主要内容
临床试验/JPRN-UMIN000015802
JPRN-UMIN000015802已完成未知

Impact of the Landiolol on the level on serum biomarkers, catecholamines and cardiac enzymes in patients with coronary artery disease performed percutaneouse coronary intervention. - Impact of the Landiolol on the level on serum biomarkers, catecholamines and cardiac enzymes in patients with coronary artery disease performed percutaneouse coronary intervention.

Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine0 个研究点目标入组 70 人开始时间: 2014年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
70

研究概览

简要总结

Serum APN and HMW-APN level 3 days after PCI were similar between patients treated with and without landiolol. APN and HMW-APN decreased 1 day after PCI in the SAP and landiolol mitigated decrease in HMW-APN.

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. HR less than 50bpm 2. 2or3 AV block 3. Shock 4. Left main disease 5. Asthma 6. Right ventricular infarction 7. History of side effects by using beta blockers 8. Symptom of heart failure 9. Patients with malignancy, uncontrolled infection 10. Patients who need hemodialysis 11. PCI for chronic total occlusion 12. Reduced ejection fraction (<40%) 13. Pregnant 14. Patients who used Landiolol within 1 month before PCI 15. Not eligible determined by the responding physician

研究者

发起方
Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine

相似试验